Latest Breaking News On - Pascal prigent - Page 5 : comparemela.com

GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update

Cash, cash equivalents and current financial assets totaled €111.8 million as of June 30, 2023 Positive results in the pivotal Phase 3 ELATIVE® trial in June 2023, paving the way to: a potential submission to the

GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update

GENFIT Reports First Half-Year 2023 Financial Results and

Cash, cash equivalents and current financial assets totaled €111.8 million as of June 30, 2023 Positive results in the pivotal Phase 3 ELATIVE® trial in.

Ipsen : and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership -Today at 07:50 am

Agreement gives Ipsen global1 rights to develop and commercialize GENFIT s late-stage, first-in-class PPAR alpha and delta agonist elafibranor in Primary Biliary Cholangitis .

'Encouraging' ELATIVE data for elafibranor may spark race for primary biliary cholangitis